Welcome to the future of biopharmaceutical R&D and Manufacturing. Our advanced metabolic-strain engineering and purification platforms enable revolutionary efficiencies in biopharmaceutical discovery and manufacturing.

Accelerate the drug discovery process using AbSci’s all-in-one protein expression platform, SoluPro™. The optimization process enables rapid expression of soluble, complex proteins in high yields, and puts the focus on screening lead candidates instead of producing them.

SoluPro™, AbSci’s next-generation E. coli expression platform, generates diverse protein products at unparalleled yields compared to current manufacturing processes. Our technologies decrease COGs, reduce production times, and significantly increase plant capacity.

SoluPro™, our all-in-one protein expression platform, produces complex proteins ranging from full-length antibodies to insulin using the simplest, best studied, and least expensive organism, E. coli.

AbSci Advantages

>20g/L

UNPRECEDENTED FERMENTATION TITERS

SoluPro™ expression platform produces complex disulfide bonded proteins in a properly folded, soluble form

>75%

PURITY PRIOR TO CHROMATOGRAPHY

SoluPure™ ‘no-column’ purification technology eliminates downstream chromatography steps

10-20x

INCREASE IN PLANT PRODUCTIVITY

SoluPro™ and SoluPure™ increase manufacturing flexibility and enables multi-product facilities

Up to 80%

REDUCTION IN DRUG SUBSTANCE COSTS

SoluPro™ and SoluPure™ enable dramatic cost savings compared to existing biomanufacturing processes

Ultra-High Yield Streamlined Protein Production

OUR TECHNOLOGY

Two key innovations form the foundation of our SoluPro™ protein expression platform: a carefully engineered semi-oxidizing cytoplasm and a dual inducible promoter system that enables precision control over protein production rates. AbSci’s unprecedented approach and proprietary understanding of protein folding enables SoluPure a chromatography-free purification method that removes downstream processing bottlenecks.

This scalable downstream purification technique utilizes existing standard to remove host-cell proteins and eliminate downstream chromatography steps. Together, SoluPure™ and SoluPro™ introduce numerous efficiencies throughout biologic discovery and manufacturing by providing rapid access to therapeutic candidates, simplifying downstream purification, and achieving fermentation titers that can be measured in tens of grams per liter.

Traditionally, protein expression in E. coli is achieved either through cytoplasmic production as inclusion bodies or through secretion into the periplasmic space.  SoluPro™ expresses soluble, disulfide linked proteins through production in a semi-oxidized cytoplasm.

SoluPro’s™ precisely tunable dual inducer system achieves peak production using straightforward induction titrations. Below is an example of Fab expression.

SoluPro™ speeds the time it takes to get new medicines to market by accelerating, or in some cases, cutting out steps entirely from the drug discovery and clinical development process. During development, SoluPro™ can produce gram quantities of material for preliminary screenings in a matter of days instead of weeks. In addition, because SoluPro™ has a demonstrated track record expressing difficult proteins and achieves higher protein production levels than mammalian systems, scientists can now access previously elusive and untestable therapeutic proteins. Once therapeutic candidates have been identified, the platform scales seamlessly for commercial production, therefore eliminating the 6-12 month cell-line development process.

At scale, SoluPro™ creates breakthrough efficiencies in biomanufacturing, eliminating the need for large plant build-outs and reducing drug substance costs by 50-80% for high-volume medicines such as insulin. By returning biomanufacturing to its E. coli roots, AbSci aims to replace CHO and other mammalian expression platforms as the expression host of choice.

PARTNERSHIPS

Molecules

Partners

PARTNERSHIPS

AbSci collaborates with leading pharmaceutical companies to enable step-changes in productivity to their bio-pharmaceutical R&D and manufacturing.

AbSci is supported by a syndicate of experienced investors:

“People in the industry have been talking about folding protein in E. coli for years. Before it was just theoretically possible, but the SoluPro™ Platform now makes it technically possible to fold full-length antibodies and proteins in E. coli.”

Fred Larimore, PhD, Former Research Fellow at Eli Lilly

ABOUT US

We are a fearless, intellectually energetic team of scientists continually defining the future of drug discovery and manufacturing for the biopharmaceutical industry.

AbSci scientists are iconoclasts, defying established industry practices, resolute in a shared conviction that the status quo for biomanufacturing is obsolete. We attract passionate, imaginative and accomplished scientists who are risk takers, keen to experiment, collaborate and create extraordinary drug discovery and manufacturing tools to disrupt and transform how life-changing biologics are made.

Our Scientific Advisory Board and Board of Directors are comprised of world-class scientists who bring decades of experience leading and igniting the biotech industry in all facets of drug discovery and biomanufacturing.

 

Sean McClain

Sean is a biotech innovator and entrepreneur who defies established approaches to biomanufacturing and drug development. While earning his degrees in biochemistry and molecular biology, McClain began developing a revolutionary new protein expression platform. McClain has since invented several patented technologies and under his leadership AbSci has grown into a global leader in the biomanufacturing industry.

Sean McClain

Founder & CEO

Suzanne Sprunger, Ph.D., J.D

Suzanne has a Ph.D. in Genetics from the University of Wisconsin and worked as a patent attorney for Wyeth, Immunex, and Amgen.  She has directed AbSci’s patent portfolio since 2012, and now serves as Chief Intellectual Property Officer.

Suzanne Sprunger, Ph.D., J.D.

Chief Intellectual Property Officer

Phil Barish, Ph.D.

Phil has 15 years research experience in protein expression, engineering, and gene therapy.  As a member of the AbSci team, Dr. Barish has invented and developed several breakthrough biomanufacturing technologies. He currently leads a team of scientists in the development and implementation of AbSci’s technologies as part of the company’s ongoing strategic partnerships.

Phil Barish, Ph.D.

VP, Research and Operations

Penelope

The face of AbSci. Always eager to welcome guests. She lives on the finest doggy treats and lunchtime spills. Her four years’ experience as a loyal friend is always helpful. But what she brings most to the team is an extensive understanding of chew toys and Frisbee games.

Penelope

Chief Morale Officer

Shelley Klassen, CPA, CMA

Shelley has a Bachelors of Science in Accounting from the University of Kentucky. For nearly 20 years, she has worked for both established and startup companies across a variety of industries in the role of public accountant, Controller, and CFO. She has served as Chief Financial Officer for AbSci since March 2016.

Shelley Klassen, CPA, CMA

Chief Financial Officer

Dan Hunt

Dan has served in senior roles as general counsel for multiple large biotech companies during his 25 year career, including Genentech, Abgenix (now Amgen), Roche, and Chiron. He brings extensive experience integrating science, business development, and legal disciplines which he leverages to manage AbSci’s licensing, contracts, and patent strategy.

Dan Hunt

Licensing and Transaction Counsel

Zachariah Jonasson, Ph.D.

Dr. Jonasson is a co-founder and Managing Partner at Phoenix Venture Partners. He has founded multiple biotechnology companies and currently serves on the board of several biotech companies. Dr. Jonasson is an alumni of the Kauffman Fellowship program and has led investments in advanced materials and life science startups over the past 25 years.

Zach Jonasson, Ph.D.

Chairman, Managing Partner PVP

V. Bryan Lawlis Ph.D.

Dr. Lawlis is a renowned bioprocessing scientist and executive with over 36 years of experience in the biotech industry. He started his career at Genentech, working there from 1981-1996, ultimately serving as Vice President of Process Engineering. He has since founded multiple companies, acting as CEO for Itero Biopharmaceuticals, Aradigm, FUJIFILM Diosynth, and Covance. He currently holds board appointments at BioMarin, Coherus, Geron, Sutro, and Reform Biologics, and is an advisor to Phoenix Venture Partners.

V. Bryan Lawlis, Ph.D.

Independent Consultant

Sean McClain

Sean is a biotech innovator and entrepreneur who defies established approaches to biomanufacturing and drug development. While earning his degrees in biochemistry and molecular biology, McClain began developing a revolutionary new protein expression platform. McClain has since invented several patented technologies and under his leadership AbSci has grown into a global leader in the biomanufacturing industry.

Sean McClain

Founder & CEO

Dan Gold, Ph.D.

Dr. Gold is a widely recognized leader in bioprocessing with expertise in upstream, downstream, formulation, and analytical development. He has over 30 years of industry experience as both a scientist and executive, including Genentech, Human Genome Sciences, Covance, and Sutro Biopharma, where he acted as CEO. Dr. Gold is currently Vice President of Process Sciences at BioMarin where he oversees all bioprocessing activities.

Dan Gold, Ph.D.

VP Process Sciences, BioMarin

Phil Barish, Ph.D.

Phil has 15 years research experience in protein expression, engineering, and gene therapy.  As a member of the AbSci team, Dr. Barish has invented and developed several breakthrough biomanufacturing technologies. He currently leads a team of scientists in the development and implementation of AbSci’s technologies as part of the company’s ongoing strategic partnerships.

Phil Barish, Ph.D.

VP of Operations and R&D

V. Bryan Lawlis, Ph.D

Dr. Lawlis is a renowned bioprocessing scientist and executive with over 36 years of experience in the biotech industry. He started his career at Genentech, working there from 1981-1996, ultimately serving as Vice President of Process Engineering. He has since founded multiple companies, acting as CEO for Itero Biopharmaceuticals, Aradigm, FUJIFILM Diosynth, and Covance. He currently holds board appointments at BioMarin, Coherus, Geron, Sutro, and Reform Biologics, and is an advisor to Phoenix Venture Partners.

V. Bryan Lawlis, Ph.D.

Chairman, Independent Consultant

Bill Bennett, Ph.D.

Dr. Bennett is a renowned specialist in downstream process development and regulatory affairs. He spent 18 years at Genentech in various roles, rising to Sr. Director of Regulatory Policy and leading the Genentech Biosimilars working group. Since Genentech, he has held various Senior roles in the biotech industry. Dr. Bennett’s work on blood platelets, neurobiology, human growth hormone and tissue-type plasminogen activator, have fueled medicines that have saved thousands of lives.

Bill Bennett, Ph.D.

Principal, Bioscope Associates

Dan Gold, Ph.D.

Dr. Gold is a widely recognized leader in bioprocessing with expertise in upstream, downstream, formulation, and analytical development. He has over 30 years of industry experience as both a scientist and executive, including Genentech, Human Genome Sciences, Covance, and Sutro Biopharma, where he acted as CEO. Dr. Gold is currently Vice President of Process Sciences at BioMarin where he oversees all bioprocessing activities.

Dan Gold, Ph.D.

VP Process Sciences, BioMarin

Fred Larimore, Ph.D

Dr. Larimore has over 30 years of experience in development and manufacturing of recombinant proteins. During his tenure at Eli Lilly as a senior scientific leader, he led manufacturing support for six major biotechnology products in the marketplace, including Xigris®, Humulin®, Humalog®, Humatrope®, Forteo® and Recombinant Human Glucagon. He was influential in developing some of the original biologic manufacturing processes that resulted in scale-up of insulin production.

Fred Larimore, Ph.D.

Principal, Sierra Vista Biotech

Alan Herman, Ph.D.

Dr. Herman is a pioneer in protein analysis and characterization. He has been influential in establishing guidelines and concepts that are currently used biologics characterization. During his 30-year career, Dr. Herman has worked at numerous biotech companies, including Genentech, Merck, and Amgen, and is currently CSO at Coherus Bioscience.

Alan Herman, Ph.D.

CSO Coherus

“AbSci reminds me of Genentech in the early 80’s, they’ve taken on some really hard problems to explain and there’s no fear around solving these key industry issues.”

V. Bryan Lawlis, PhD, Former VP of Process Science at Genentech

CAREERS

Join the Team | Change an Industry

At AbSci, we defy established protein expression conventions and continually invent new technologies and approaches which introduce efficiencies and cost savings to the biotech industry. We are looking for original thinkers, accomplished and energetic scientists who have the imagination to join us and re-define what’s possible.

Senior Scientist

Purification

Qualifications:
PhD in Life Sciences or related scientific discipline with 4+ years of industry experience in process development. Expertise in developing scalable, downstream purifi…

APPLY NOW

Senior Research Associate

Purification

Qualifications:
BS or MS degree in Biochemistry or related scientific discipline, 4 years post-graduate research experience, expert at SDS-PAGE and Western Blotting, experience with a diverse…

APPLY NOW

Associate Scientist

Purification

Qualifications:
BS or MS degree in a related scientific discipline with 5+ years of research experience in an industry environment, or a PhD with 0-2 years of relevant postgraduate…

APPLY NOW
NEWS / UPDATES / PRESS

AbSci Named Washington 100 Best Companies to Work For

We’re excited to announce that AbSci made Seattle Business Magazine’s list of Washington’s 100 Best Companies to Work For! This year marks the 29th annual release of the Seattle Business Magazine’s 100 Best Companies to Work For list, as they look for the top...

read more

101 E 6th Street, Suite 300, Vancouver, WA 98660 Tel. 360-949-1041

Terms / Privacy / Cookie Policy / © Copyright 2018 Absci LLC

Absci Vancouver

Absci 101 E 6th Street, Suite 300, Vancouver, WA 98660